Burn infections

Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military settingR327G to be evaluated as a potential replacement for traditional antimicrobial dressings and topicals used in the military setting SYDNEY, July 16, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced it has been awarded $2 million in grant funding from the U.S. Department of Defense in recognition of RECCE® 327 Gel (R327G) as a topical treatment for burn wound infections. “We are honored by the U.S. Department of Defense’s decision to award grant funding for R327G, as it underscores our commitment to advancing medical solutions critical to military personnel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “This recognition is a testament to our technology’s unique profile and high-quality R&D. We look forward to working closely with the U.S. Department of Defense to progress our research efforts and fulfill our commitment to improving global health outcomes.” The grant funding from the U.S. Department of Defense Congressionally Directed Medical Research Programs (CDMRP) will enable the Company to accelerate the development of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections and minimize the onset of bacteremia complications, such as sepsis. The project aims to establish the potential for R327G products for use in a point-of-injury military setting. The CDMRP includes the Military Burn Research Program (MBRP) Technology/Therapeutic Development Award, managed by the U.S. Department of Defense, that focuses on supporting biomedical research to advance technologies or therapies in areas of critical importance to the military and civilian populations, such as burn wound injuries. The MBRP Technology/Therapeutic Development Award application is a specific grant designed to support projects focused on developing technologies or therapies for burn injuries, particularly those relevant to military personnel. The Company’s application received an overall evaluation of 1.4 (Outstanding) based on a rating scale of 1 (highest merit) to 5 (lowest merit). It was assessed on three criteria, with a rating scale of 10 (highest merit) to 1 (lowest merit): research strategy and feasibility (8.2), impact and military benefit (8.8), and transition plan and regulatory strategy (9.0). “Given their excellent preliminary data and the relatively low therapeutic index required in topical antimicrobials, it seems likely that the product would be a success,” said a scientific reviewer. A separate scientific reviewer commented on the Company’s proposal, saying, “If the proposed product is successful, it would improve the quality of life and shorten recovery and healing times for the burned individual.” In addition to the grant, the Company has successfully completed an A$8 million institutional placement, with an opened share purchase plan (SPP) to raise up to A$2 million, available until July 31, 2024. Investors can access the share purchase plan through the ASX website under the ticker ASX: RCE, Recce’s official website at Company Announcements, or via the Automic website. This strategic financial move underscores Recce's commitment to advancing innovative therapies and strengthening its market presence. About Recce Pharmaceuticals LtdRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development. Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies. Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 9256 2571James.graham@recce.com.au Media & Investor Relations (AU)Andrew GeddesCityPR+61 (02) 9267 4511ageddes@citypublicrelations.com.au Media (USA)Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com Investor Relations (USA & EU)Guillame van RenterghemLifeSci Advisorsgvanrenterghem@lifesciadvisors.com

Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens during testing with Linnaeus BioscienceU.S. Department of Defense has recommended RECCE® 327 Gel (R327G) as a topical treatment for burn wound infections for grant funding of $2.2 millionSubmission of Investigational New Drug (IND) application with the U.S. FDA expected in H2 2024 for U.S. trial initiation in H1 2025Continued recognition and awareness of Recce with presentations recently presented at the Biomedical Advanced Research and Development Authority (BARDA), opening keynote address and opening R&D address at the World AMR Congress 2024 and sponsorship received from Western Australia (WA) and New South Wales (NSW) government for the BIO International Convention 2024 SYDNEY, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (Recce or the Company), a leading developer of a new class of synthetic anti-infectives, today provided a business update highlighting various ongoing activities and progress made since the Annual General Meeting held on November 8, 2023. Detailed Update: Progress of R327 across Multiple Indications (UTI/Urosepsis, DFI, Topical Wounds, SAS-A) Phase I/II UTI/Urosepsis Trial – R327 Achieving Minimum Inhibitory Concentration (MIC) The Company is making significant strides in its Phase I/II trial for UTIs and urosepsis. Recent clinical urine samples have indicated promising MIC activity, suggesting that fast infusion of R327 leads to concentrations capable of blocking the growth of bacteria in urine, which is relevant for the treatment of patients with UTIs and urosepsis, in a safe and tolerable manner. This promising finding has prompted the Company to increase the dosage of R327 in this Phase I/II trial to its highest level yet, at a rate of 4,000mg infused over 30 minutes, which is expected to begin by the end of Q2 2024. This escalation reflects the significant progress surrounding R327's potential to address critical medical needs in the treatment of UTIs and urosepsis. DFI Efficacy Achieved: Expansion of Phase I/II DFI Clinical Trial Recce is actively pursuing an expansion of its clinical trial sites for its Phase I/II trial evaluating R327 in patients with DFIs, with notable sites identified and expected to come online during the present quarter, including one of the largest and most comprehensive regional health services in Australia based out of Victoria, and a world-class private hospital in Western Australia. This strategic initiative aims to access a greater patient population, enhancing the diversity and depth of clinical data gathered. By forging collaborations with these esteemed institutions, the Company continues to demonstrate its commitment to advancing medical research and delivering innovative solutions that could potentially transform patient outcomes. The Company is actively advancing its latest international expansion in Indonesia for a DFI clinical trial, moving steadily towards the initiation of a Phase III registrational trial scheduled to commence in Q3 2024. R327 works and keeps on working with repeated use: tested in more than 300 Strains of Bacterial Pathogens – Effective Against All The Company continues to work with leading experts dedicated to the discovery and development of innovative technologies, Linnaeus Bioscience, where they have tested R327 against more than 300 strains between the ESKAPE group of pathogens (198 Gram-negative and 111 Gram-positive bacteria strains). Chief Operations Officer of Linnaeus, Hannah Tsunemoto, Ph.D., led the experiments against these pathogens and commented, “R327 is effective against all strains tested at MICs.” Gram-positive representatives Gram-negative representativesBacteriaStrains BacteriaStrainsEnterococcus spp.33 K. pneumoniae38S. aureus65 A. baumannii53Enterobacter spp.13 P. aeruginosa63 Salmonella4Total198 E. coli40 Total111 More than 95% of the strains tested were clinically isolated from a variety of sources, including but not limited to wounds, blood, urine, and sputum (phlegm). Furthermore, in a 31-day sub-MIC serial exposure study, R327 was tested against a Multi-Drug Resistant (MDR) strain of Escherichia coli (E. coli) and showed no evidence of induced resistance to R327. Submission of Investigational New Drug (IND) Application with the US FDA expected in H2 2024 for U.S. trial initiation in H1 2025 The Company has been making significant strides in preparing for an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). One of the pivotal initiatives contributing to this progress is the successful ongoing Phase I/II UTI/Urosepsis rapid infusion clinical trial. The completion of the Phase I trial marked a crucial milestone for the Company, providing valuable data on the safety and tolerability of R327 required as part of the IND Application dossier. As the Company continues to generate promising interim data from its Phase I/II UTI/Urosepsis clinical trial on both safety and efficacy, R327 is showcasing its capability to be administered over multiple fast infusion times, highlighting the potential for a ground-breaking treatment on the first patient presentation in any medical setting. These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly. The Company expects to open a second IND application for all topical work conducted soon after the intravenous (IV) IND application. Government/Private Enterprise Partnerships and Presence in the USA Recce has been actively pursuing various grant applications and submissions, particularly in government antimicrobial resistance (AMR) initiatives and military and health security. U.S. Department of Defense: Recommended for $2.2M Grant Funding As a result of the Company's efforts in the military sector, the U.S. Department of Defense has recommended R327 Gel (R327G) as a topical treatment for burn wound infections for grant funding of $2.2 million. Once awarded, the funding will enable the Company to accelerate the development and evaluation of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections and minimize the onset of bacteremia complications, such as sepsis. This milestone emphasizes the Company’s significant contributions to military health research. Recce expects funding to be received in H1 2024. Biomedical Advanced Research and Development Authority (BARDA) Presentation Recce delivered a company presentation at the request of the U.S. Biomedical Advanced Research and Development Authority (BARDA), further strengthening its relationship and collaboration with U.S. governmental organizations. BARDA has specific areas of interest that it focuses on for funding, where R327 fits into two categories: Antimicrobials (3.1 Multi-drug resistant Bacteria and Biothreat Pathogens) and Burn and Blast Medical Countermeasures (6.4 Non-Autologous Topical Products for Acute bacterial skin and skin structure infections). The presentation was well received and attended by members of the U.S. government from respective military fields. WA and NSW Government Sponsor Recce for BIO International Convention 2024 The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. As part of the Company’s national government initiatives, Recce has been successfully selected to be part of the WA and NSW delegation at BIO 2024, highlighting its regional support and recognition within the biopharmaceutical community. These initiatives collectively demonstrate Recce's dedication to advancing innovative solutions in healthcare through strategic collaborations and impactful research endeavours. World AMR Congress 2024: Opening Keynote Address and the Opening R&D Address The Company has received another prestigious invitation to present the opening R&D address at the World AMR Congress. In recognition of its global initiatives, the Company has also been privileged with the opportunity to deliver the opening keynote address for the entire congress. John Prendergast, Ph.D., Recce’s Executive Chairman, will deliver the opening R&D address, while Alan W. Dunton, M.D., Recce’s Chief Medical Advisor and Non-Executive Director, will open the Congress with the opening keynote. Poster Presentation - American Society for Clinical Pharmacology and Therapeutics Michele Dilizia, Recce’s Chief Scientific Officer and Co-inventor of RECCE® technology, presented a poster based on the results of a Phase I trial at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, showcasing the company's scientific advancements. The annual meeting serves as a multi-disciplinary catalyst for emerging science, focused on the integrity and diversity of clinical pharmacology and translational medicine. Military Health System Research Symposium (MHSRS) Abstract Submission As was delivered in 2023, the Company has again submitted an abstract for MHSRS 2024, building on its successful participation in 2023 and anticipating further success this year. The MHSRS is the U.S. Department of Defense’s foremost scientific meeting, presenting new scientific knowledge particular to military specific R&D. Additional Operational Activities World Health Organization Recognition R327, along with R435 and R529, gained recognition from the World Health Organization (WHO) by being added to their list of antibacterial products in clinical development for priority pathogens. This acknowledgment highlights the potential of RECCE® compounds to address critical global health challenges posed by antibiotic-resistant bacteria. Being included in the WHO's evaluation signifies the importance of Recce’s research and development efforts in combatting infectious diseases. The WHO annually assesses antibacterial products, which involves an evaluation comparing these products in development with the WHO's list of antibiotic-resistant bacterial priority pathogens. R&D Advance Initiatives – Endpoints Capital The Company continues to strengthen its strategic partnership with Endpoints Capital after securing a significant $11.2 million in non-dilutive funding, reinforcing its R&D initiatives for FY23/24 and into the future. This financial support, augmented by the Advanced Overseas Finding from the Australian Government, expands Recce's R&D horizons globally. For more insights into this partnership, Recce and Endpoints have released an on-camera podcast interview that discusses the influence of their collaboration on Recce's growth and the biotech industry, which can be accessed here. About Recce Pharmaceuticals LtdRecce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy. Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs. Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 9256 2571James.graham@recce.com.au Media & Investor Relations (AU)Andrew GeddesCityPR+61 (02) 9267 4511ageddes@citypublicrelations.com.au Media (USA)Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com Investor Relations (USA & EU)Guillame van RenterghemLifeSci Advisorsgvanrenterghem@lifesciadvisors.com

Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeks Expansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024 RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens during testing with Linnaeus Bioscience U.S. Department of Defense has recommended RECCE® 327 Gel (R327G) as a topical treatment for burn wound infections for grant funding of $2.2 million Submission of Investigational New Drug (IND) application with the U.S. FDA expected in H2 2024 for U.S. trial initiation in H1 2025 Continued recognition and awareness of Recce with presentations recently presented at the Biomedical Advanced Research and Development Authority (BARDA), opening keynote address and opening R&D address at the World AMR Congress 2024 and sponsorship received from Western Australia (WA) and New South Wales (NSW) government for the BIO International Convention 2024 SYDNEY, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (Recce or the Company), a leading developer of a new class of synthetic anti-infectives, today provided a business update highlighting various ongoing activities and progress made since the Annual General Meeting held on November 8, 2023. Detailed Update: Progress of R327 across Multiple Indications (UTI/Urosepsis, DFI, Topical Wounds, SAS-A) Phase I/II UTI/Urosepsis Trial – R327 Achieving Minimum Inhibitory Concentration (MIC) The Company is making significant strides in its Phase I/II trial for UTIs and urosepsis. Recent clinical urine samples have indicated promising MIC activity, suggesting that fast infusion of R327 leads to concentrations capable of blocking the growth of bacteria in urine, which is relevant for the treatment of patients with UTIs and urosepsis, in a safe and tolerable manner. This promising finding has prompted the Company to increase the dosage of R327 in this Phase I/II trial to its highest level yet, at a rate of 4,000mg infused over 30 minutes, which is expected to begin by the end of Q2 2024. This escalation reflects the significant progress surrounding R327's potential to address critical medical needs in the treatment of UTIs and urosepsis. DFI Efficacy Achieved: Expansion of Phase I/II DFI Clinical Trial Recce is actively pursuing an expansion of its clinical trial sites for its Phase I/II trial evaluating R327 in patients with DFIs, with notable sites identified and expected to come online during the present quarter, including one of the largest and most comprehensive regional health services in Australia based out of Victoria, and a world-class private hospital in Western Australia. This strategic initiative aims to access a greater patient population, enhancing the diversity and depth of clinical data gathered. By forging collaborations with these esteemed institutions, the Company continues to demonstrate its commitment to advancing medical research and delivering innovative solutions that could potentially transform patient outcomes. The Company is actively advancing its latest international expansion in Indonesia for a DFI clinical trial, moving steadily towards the initiation of a Phase III registrational trial scheduled to commence in Q3 2024. R327 works and keeps on working with repeated use: tested in more than 300 Strains of Bacterial Pathogens – Effective Against All The Company continues to work with leading experts dedicated to the discovery and development of innovative technologies, Linnaeus Bioscience, where they have tested R327 against more than 300 strains between the ESKAPE group of pathogens (198 Gram-negative and 111 Gram-positive bacteria strains). Chief Operations Officer of Linnaeus, Hannah Tsunemoto, Ph.D., led the experiments against these pathogens and commented, “R327 is effective against all strains tested at MICs.” Gram-positive representatives Gram-negative representatives Bacteria Strains Bacteria Strains Enterococcus spp. 33 K. pneumoniae 38 S. aureus 65 A. baumannii 53 Enterobacter spp. 13 P. aeruginosa 63 Salmonella 4 Total 198 E. coli 40 Total 111 More than 95% of the strains tested were clinically isolated from a variety of sources, including but not limited to wounds, blood, urine, and sputum (phlegm). Furthermore, in a 31-day sub-MIC serial exposure study, R327 was tested against a Multi-Drug Resistant (MDR) strain of Escherichia coli(E. coli) and showed no evidence of induced resistance to R327. Submission of Investigational New Drug (IND) Application with the US FDA expected in H2 2024 for U.S. trial initiation in H1 2025 The Company has been making significant strides in preparing for an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). One of the pivotal initiatives contributing to this progress is the successful ongoing Phase I/II UTI/Urosepsis rapid infusion clinical trial. The completion of the Phase I trial marked a crucial milestone for the Company, providing valuable data on the safety and tolerability of R327 required as part of the IND Application dossier. As the Company continues to generate promising interim data from its Phase I/II UTI/Urosepsis clinical trial on both safety and efficacy, R327 is showcasing its capability to be administered over multiple fast infusion times, highlighting the potential for a ground-breaking treatment on the first patient presentation in any medical setting. These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly. The Company expects to open a second IND application for all topical work conducted soon after the intravenous (IV) IND application. Government/Private Enterprise Partnerships and Presence in the USA Recce has been actively pursuing various grant applications and submissions, particularly in government antimicrobial resistance (AMR) initiatives and military and health security. U.S. Department of Defense: Recommended for $2.2M Grant Funding As a result of the Company's efforts in the military sector, the U.S. Department of Defense has recommended R327 Gel (R327G) as a topical treatment for burn wound infections for grant funding of $2.2 million. Once awarded, the funding will enable the Company to accelerate the development and evaluation of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections and minimize the onset of bacteremia complications, such as sepsis. This milestone emphasizes the Company’s significant contributions to military health research. Recce expects funding to be received in H1 2024. Biomedical Advanced Research and Development Authority (BARDA) Presentation Recce delivered a company presentation at the request of the U.S. Biomedical Advanced Research and Development Authority (BARDA), further strengthening its relationship and collaboration with U.S. governmental organizations. BARDA has specific areas of interest that it focuses on for funding, where R327 fits into two categories: Antimicrobials (3.1 Multi-drug resistant Bacteria and Biothreat Pathogens) and Burn and Blast Medical Countermeasures (6.4 Non-Autologous Topical Products for Acute bacterial skin and skin structure infections). The presentation was well received and attended by members of the U.S. government from respective military fields. WA and NSW Government Sponsor Recce for BIO International Convention 2024 The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. As part of the Company’s national government initiatives, Recce has been successfully selected to be part of the WA and NSW delegation at BIO 2024, highlighting its regional support and recognition within the biopharmaceutical community. These initiatives collectively demonstrate Recce's dedication to advancing innovative solutions in healthcare through strategic collaborations and impactful research endeavours. World AMR Congress 2024: Opening Keynote Address and the Opening R&D Address The Company has received another prestigious invitation to present the opening R&D address at the World AMR Congress. In recognition of its global initiatives, the Company has also been privileged with the opportunity to deliver the opening keynote address for the entire congress. John Prendergast, Ph.D., Recce’s Executive Chairman, will deliver the opening R&D address, while Alan W. Dunton, M.D., Recce’s Chief Medical Advisor and Non-Executive Director, will open the Congress with the opening keynote. Poster Presentation - American Society for Clinical Pharmacology and Therapeutics Michele Dilizia, Recce’s Chief Scientific Officer and Co-inventor of RECCE® technology, presented a poster based on the results of a Phase I trial at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, showcasing the company's scientific advancements. The annual meeting serves as a multi-disciplinary catalyst for emerging science, focused on the integrity and diversity of clinical pharmacology and translational medicine. Military Health System Research Symposium (MHSRS) Abstract Submission As was delivered in 2023, the Company has again submitted an abstract for MHSRS 2024, building on its successful participation in 2023 and anticipating further success this year. The MHSRS is the U.S. Department of Defense’s foremost scientific meeting, presenting new scientific knowledge particular to military specific R&D. Additional Operational Activities World Health Organization Recognition R327, along with R435 and R529, gained recognition from the World Health Organization (WHO) by being added to their list of antibacterial products in clinical development for priority pathogens. This acknowledgment highlights the potential of RECCE® compounds to address critical global health challenges posed by antibiotic-resistant bacteria. Being included in the WHO's evaluation signifies the importance of Recce’s research and development efforts in combatting infectious diseases. The WHO annually assesses antibacterial products, which involves an evaluation comparing these products in development with the WHO's list of antibiotic-resistant bacterial priority pathogens. R&D Advance Initiatives – Endpoints Capital The Company continues to strengthen its strategic partnership with Endpoints Capital after securing a significant $11.2 million in non-dilutive funding, reinforcing its R&D initiatives for FY23/24 and into the future. This financial support, augmented by the Advanced Overseas Finding from the Australian Government, expands Recce's R&D horizons globally. For more insights into this partnership, Recce and Endpoints have released an on-camera podcast interview that discusses the influence of their collaboration on Recce's growth and the biotech industry, which can be accessed here. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy. Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs. Corporate Contact James Graham Recce Pharmaceuticals Ltd +61 (02) 9256 2571 James.graham@recce.com.au Media & Investor Relations (AU) Andrew Geddes CityPR +61 (02) 9267 4511 ageddes@citypublicrelations.com.au Media (USA) Michael Fitzhugh LifeSci Communications mfitzhugh@lifescicomms.com Investor Relations (USA & EU) Guillame van Renterghem LifeSci Advisors gvanrenterghem@lifesciadvisors.com